Showing 1201-1210 of 1576 results for "".
- Johnson & Johnson Vision Announces FDA Approval Of Tecnis Synergy And Tecnis Synergy Toric II IOLs In the UShttps://modernod.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/Johnson & Johnson Vision announced the FDA approval of Tecnis Synergy and Tecnis Synergy Toric II IOLs, and the Health Canada approval of Tecnis Synergy Toric II IOLs. This next-generation PCIOL is built on the legacy Tecnis platform and delivers a wide range of continuous vision with
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Johnson & Johnson Vision Receives Approval in Canada for First Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-first-drug-releasing-contact-lens-for-vision-correction-and-allergic-eye-itch/2479117/Johnson & Johnson Vision received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: Acuvue Theravision with Ketotifen.1 The lens contains an H1 hista
- Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/Johnson & Johnson Vision announced the FDA 510(k) clearance and CE mark of its next-generation phacoemulsification device, the Veritas Vision System. The phaco system features technologies that allow surgeons to guide through any lens density with less surge and more stability. The new system
- Johnson & Johnson Vision Introduces Acuvue Abiliti to Address Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-abiliti-to-address-myopia-in-children/2479101/Johnson & Johnson Vision announced the launch of Acuvue Abiliti, a new brand for future products and services aimed at helping parents and eye care providers address the growing prevalence and progression of myopia in children. Abiliti will provide parents and eye care providers with c
- Feds Call Halt to Johnson & Johnson COVID-19 Vaccine Rollout After ‘Extremely Rare’ Blood Clot Caseshttps://modernod.com/news/feds-call-halt-to-johnson-johnson-covid-19-vaccine-rollout-after-extremely-rare-blood-clot-cases/2479070/After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials are calling fo
- Johnson & Johnson Takes Charge of Emergent COVID-19 Vaccine Manufacturing Sitehttps://modernod.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/The US Department of Health & Human Services (HHS) has put Johnson & Johnson in charge of the Emergent BioSolutions’ Bayview facility in Baltimore, which ruined around 15 million doses of its COVID-19 vaccine Ad26.COV2.S. Johnson & Johnson said it was “assuming full
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt
- Johnson & Johnson Vision Receives Approval in Japan for First Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/Johnson & Johnson Vision announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch: Acuvue Theravision with Ketotifen. The lens contains ketotifen, an H1 histamine receptor antagonis
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.